RxDoctor Payments Data

Ashley Eiferle

Medical · Las Vegas, NVNPI 1457776999

Payments from drug & device makers

$2,159in general payments, 2019–2025

Across 46 payments — averaging $46.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$324
  • Boehringer Ingelheim$201
  • Philips North America LLC$199
  • Abiomed$157
  • Atricure, Inc.$156
  • Boston Scientific$150
  • plus $971 from 13 others

What the payments were for

  • Food & beverage$2,159100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,159 in reported general payments places this provider in the 65th percentile of 250 medical providers in Nevada.

See all medical providers in Nevada

Medicare billing

Part B allowed, 2024
$52,816
Medicare patients
336
Services billed
683

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$308,643
Repatha SureclickEvolocumab81$73,989
XareltoRivaroxaban39$61,072
EntrestoSacubitril/Valsartan29$37,619
JardianceEmpagliflozin22$29,188
FarxigaDapagliflozin Propanediol19$26,661
BrilintaTicagrelor20$15,113
OzempicSemaglutide11$11,406
Metoprolol Succinate277$3,444
Atorvastatin Calcium347$3,157
Ranolazine ErRanolazine21$2,795
Ezetimibe106$2,104
Losartan Potassium184$1,714
Telmisartan35$1,613
Valsartan57$1,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$85$308,643252 claims
AstraZenecaFarxiga, Brilinta$80$41,77439 claims
NovartisEntresto$33$37,61929 claims
Boehringer IngelheimJardiance$201$29,18822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 medical providers in Nevada.

Other medical in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →